Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma
Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma
复制标题
DOI：
10.1016/s0969-8051(97)00098-x
复制
发表时间：
1997-10-01
影响因子：
3.1
通讯作者：
Bernstein, ID
中科院分区：
文献类型：
--
作者：
Eary, JF;Krohn, KA;Bernstein, ID
对非霍奇金淋巴瘤I-131放射免疫治疗数据进行分析，以确定从生物分布研究计算的辐射吸收剂量与从患者体型得出的剂量之间是否存在预测关系。根据患者体型（MBq/kg或MBq/m2）或固定MBq剂量进行放射性治疗给药不会对关键器官产生一致的辐射吸收剂量。不提供关键正常器官的剂量估计的治疗试验不太可能成功地确定放射免疫治疗的临床作用。(C)1997年爱思唯尔科学公司
Non-Hodgkin's lymphoma I-131 radioimmunotherapy data were analyzed to determine whether a predictive relationship exists between radiation absorbed doses calculated from biodistribution studies and doses derived from patient size. Radioactivity treatment administrations scaled to patient size (MBq/kg or MBq/m(2)) or fixed MBq doses do not produce consistent radiation absorbed dose to critical organs. Treatment trials that do not provide dose estimates for critical normal organs are less likely to succeed in identifying a clinical role for radioimmunotherapy. (C) 1997 Elsevier Science Inc.